SCHEMBL9748847

SCHEMBL9748847

O=C(O)CSc1ncc(CC(=O)O)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.41
POLB P06746 4/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
RECQL P46063 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
APEX1 P27695 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 1/20 0.37
NOTUM Q6P988 3/20 0.37
MAP3K8 P41279 1/20 0.37
FFAR1 O14842 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CSNK2A2 P19784 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10360510 0.84 SMN1; SMN2 (0.36) L3MBTL1HPGDPOLBKMT2AMAPT
Hydrochloric Acid SCHEMBL28230004 0.83 GAA (0.42) L3MBTL1GAAHPGDPOLBKMT2A
SCHEMBL9478749 0.82 SMN1; SMN2 (0.38) L3MBTL1GAAHPGDPOLBKMT2A
SCHEMBL10688586 0.81 APEX1 (0.44) L3MBTL1GAAHPGDPOLBTDP1
SCHEMBL9478743 0.81 SMN1; SMN2 (0.34) L3MBTL1HPGDPOLBKMT2AMAPT
SCHEMBL10688417 0.74 ALDH1A1 (0.43) HPGDPOLBKMT2AMAPTAPEX1
SCHEMBL27719736 0.72 SMN1; SMN2 (0.38) HPGDPOLBKMT2AMAPTCYP3A4
SCHEMBL28861538 0.72 SMN1; SMN2 (0.49) L3MBTL1HPGDKMT2AMAPTCYP1A2
SCHEMBL9749986 0.71 LMNA (0.49) L3MBTL1GAAHPGDPOLBHSD17B10
SCHEMBL10431342 0.71 HPGD (0.40) L3MBTL1HPGDPOLBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-0194572-B1 HETEROCYCLIC SULFIDES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1992-01-02 EP disclosed
US-4762848-A IMMUNE SYSTEM STIMULANTS, CYTOSTATIC AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-09 US disclosed
EP-0194572-A1 Heterocyclic sulfides, process for their preparation and Medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG L3MBTL1 4700/4885GAA 684/4885HPGD 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.